{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:49:50Z","timestamp":1792014590768,"version":"4.4.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ctrv.2026.103213","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:23:00Z","timestamp":1789359780000},"page":"103213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Selective estrogen receptor degraders in premenopausal breast cancer: Biological activity and endpoint relevance in window of opportunity trials"],"prefix":"10.1016","volume":"150","author":[{"given":"Ana-Maria","family":"Dud\u0103u","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Zeghondy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Emile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Lottin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Aftimos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios","family":"Boussios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Xu-Vuillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oph\u00e9lie","family":"Lion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Serhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana M","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Michiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Rassy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103213_bb0005","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2026.103213_bb0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0015","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.3390\/cancers13225643","article-title":"Endocrine treatment for breast cancer patients revisited\u2014history, standard of care, and possibilities of improvement","volume":"13","author":"Nabieva","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2026.103213_bb0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41523-023-00523-4","article-title":"An emerging generation of endocrine therapies in breast cancer: a clinical perspective","volume":"9","author":"Patel","year":"2023","journal-title":"Npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2026.103213_bb0025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10549-024-07595-1","article-title":"Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences","volume":"209","author":"Scafetta","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2026.103213_bb0030","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.19.01758","article-title":"Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk","volume":"38","author":"Pistilli","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0035","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1093\/jnci\/djad109","article-title":"Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation","volume":"115","author":"Balazard","year":"2023","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2026.103213_bb0040","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(26)00313-2","article-title":"Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials","volume":"407","author":"Bradley","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103213_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176424","article-title":"Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer","volume":"969","author":"Guglielmi","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0050","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0055","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0060","doi-asserted-by":"crossref","first-page":"4594","DOI":"10.1200\/JCO.2010.28.8415","article-title":"Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer","volume":"28","author":"Di Leo","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0065","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO-24-02086","article-title":"Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial","volume":"43","author":"Kalinsky","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0070","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2026.103213_bb0075","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0080","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0085","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103213_bb0090","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast Cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0095","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.22.02746","article-title":"AMEERA-3: randomized phase II study of amcenestrant (oral selective estrogen receptor degrader) versus standard endocrine monotherapy in estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"41","author":"Tolaney","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0100","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1200\/JCO.23.02036","article-title":"Randomized phase III study of amcenestrant plus palbociclib versus letrozole plus palbociclib in estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: primary results from AMEERA-5","volume":"42","author":"Cort\u00e9s","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0105","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103213_bb0110","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0115","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","author":"Bidard","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103213_bb0120","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1200\/JCO.23.01500","article-title":"Giredestrant for estrogen receptor-positive, HER2-negative, previously treated advanced breast cancer: results from the randomized, phase II acelERA breast cancer study","volume":"42","author":"Mart\u00edn","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0125","volume":"44","author":"Turner","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0130","doi-asserted-by":"crossref","first-page":"S1561","DOI":"10.1016\/j.annonc.2025.09.026","volume":"36","author":"Mayer","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0135","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ctrv.2015.12.005","article-title":"Window of opportunity studies: do they fulfil our expectations?","volume":"43","author":"Schmitz","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2026.103213_bb0140","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ejca.2007.11.007","article-title":"Effects of fulvestrant 750mg in premenopausal women with oestrogen-receptor-positive primary breast cancer","volume":"44","author":"Young","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103213_bb0145","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1200\/JCO-25-01548","article-title":"Pharmacodynamics of camizestrant treatment in postmenopausal women with estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative primary breast cancer: results from the randomized, presurgical SERENA-3 study","volume":"44","author":"Robertson","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0150","doi-asserted-by":"crossref","first-page":"951s","DOI":"10.1158\/1078-0432.951s.11.2","article-title":"Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival","volume":"11","author":"Dowsett","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103213_bb0155","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1158\/1078-0432.CCR-24-2460","article-title":"Elacestrant in women with estrogen receptor-positive and HER2-negative early breast cancer: results from the preoperative window-of-opportunity ELIPSE trial","volume":"31","author":"Vidal","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103213_bb0160","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s44178-022-00010-z","article-title":"An appropriate treatment interval does not affect the prognosis of patients with breast cancer","volume":"1","author":"Gao","year":"2022","journal-title":"Holist Integr Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0165","doi-asserted-by":"crossref","first-page":"1024s","DOI":"10.1158\/1078-0432.CCR-05-2127","article-title":"Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer","volume":"12","author":"Dowsett","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103213_bb0170","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","article-title":"Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial","volume":"21","author":"Smith","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0175","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/s41379-022-01104-9","article-title":"Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study","volume":"35","author":"Acs","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0180","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/1097-0142(19810815)48:4<876::AID-CNCR2820480403>3.0.CO;2-Q","article-title":"Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data","volume":"48","author":"Fabian","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2026.103213_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.107277","article-title":"LBA2 A window-of-opportunity (WOO) trial of giredestrant +\/\u2212 LHRH analogue vs anastrozole + LHRHa in premenopausal patients with ER+\/HER2- early breast cancer: PREcoopERA","volume":"11","author":"Munzone","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103213_bb0190","doi-asserted-by":"crossref","first-page":"GS1","DOI":"10.1158\/1557-3265.SABCS25-GS1-10","article-title":"Abstract GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: results from the global phase III lidERA breast cancer trial","volume":"32","author":"Bardia","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103213_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100110","volume":"53","author":"Gangl","year":"2025","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"key":"10.1016\/j.ctrv.2026.103213_bb0200","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/0008-5472.CAN-23-0694","article-title":"The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4\/6 inhibitor resistance","volume":"83","author":"Lawson","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103213_bb0205","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1200\/JCO.1989.7.8.1113","article-title":"Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group","volume":"7","author":"Kaufmann","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0210","doi-asserted-by":"crossref","first-page":"S305","DOI":"10.1016\/j.annonc.2025.08.723","volume":"36","author":"Llombart Cussac","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0215","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS25-PD10-01","article-title":"Abstract PD10-01: elacestrant alone or in combination with triptorelin in premenopausal women with ER+\/HER2- early breast cancer: primary analysis from the phase 2 SOLTI-2104- Premi\u00c8Re trial","volume":"32","author":"Bellet","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103213_bb0220","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO3-19-08","article-title":"Abstract PO3\u201319-08: A phase 2 randomized pre-operative,window of opportunity trial investigating the effect of elacestrant with\/without triptorelin in premenopausal patients with HR+\/HER2- breast cancer \u2013 SOLTI-2104-Premi\u00c8Re trial","volume":"84","author":"Ezquerra","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103213_bb0225","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrclinonc.2012.21","article-title":"Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer","volume":"9","author":"Goncalves","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0230","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-19-3387","article-title":"A randomized, open-label, presurgical, window-of-opportunity study comparing the pharmacodynamic effects of the novel oral SERD AZD9496 with fulvestrant in patients with newly diagnosed ER+ HER2- primary breast cancer","volume":"26","author":"Robertson","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103213_bb0235","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3393","article-title":"A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer","volume":"15","author":"Robertson","year":"2013","journal-title":"Breast Cancer Res BCR"},{"key":"10.1016\/j.ctrv.2026.103213_bb0240","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1200\/JCO.2005.07.559","article-title":"Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists","volume":"23","author":"Dowsett","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0245","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/jnci\/djn309","article-title":"Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics","volume":"100","author":"Ellis","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2026.103213_bb0250","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1200\/JCO.2005.04.005","article-title":"Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative Anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0255","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13058-023-01626-3","article-title":"Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER+breast cancer: further results from the POETIC trial (CRUK\/07\/015)","volume":"25","author":"Bliss","year":"2023","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103213_bb0260","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"Ellis","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103213_bb0265","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13058-023-01740-2","article-title":"AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer","volume":"25","author":"Campone","year":"2023","journal-title":"Breast Cancer Res BCR"},{"key":"10.1016\/j.ctrv.2026.103213_bb0270","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1158\/1078-0432.CCR-24-2113","article-title":"A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: results from the EMBER-2 study","volume":"30","author":"Neven","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103213_bb0275","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-026-02277-w","article-title":"A prospective single-arm pilot study evaluating [F-18]fluoroestradiol dedicated breast PET in invasive lobular carcinoma after neoadjuvant endocrine therapy","volume":"28","author":"Switalla","year":"2026","journal-title":"Breast Cancer Res"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:54Z","timestamp":1792012374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":55,"alternative-id":["S0305737226001271"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103213","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective estrogen receptor degraders in premenopausal breast cancer: Biological activity and endpoint relevance in window of opportunity trials","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103213"}}